Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL-R 40 Days Sales Outstanding is 92.45 as of Jun. 2026, which is 9% below its 10-year median of 101.87. GuruFocus rates BKK:EFORL-R with a GF Score™ of 40/100 and a GF Value™ of ฿0.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 118 Medical Distribution companies, E For L Aim PCL ranks worse than 64.41% on this metric.
The historical rank and industry rank for E For L Aim PCL's Days Sales Outstanding or its related term are showing as below:
BKK:EFORL-R'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.48 Med: 101.87 Max: 109.26
Current: 91.73
During the past 13 years, E For L Aim PCL's highest Days Sales Outstanding was 109.26. The lowest was 74.48. And the median was 101.87.
BKK:EFORL-R's Days Sales Outstanding is ranked worse than 64.41% of 118
companies
in the Medical Distribution industry
Industry Median: 74.915
vs BKK:EFORL-R: 91.73
E For L Aim PCL's Days Sales Outstanding
increased
from Jun. 2025 (80.61) to Jun. 2026 (92.45).
E For L Aim PCL (BKK:EFORL-R) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
E For L Aim PCL Days Sales Outstanding Related Terms
E For L Aim PCL Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for E For L Aim PCL's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:EFORL-R vs MCK, COR, CAH: Days Sales Outstanding Comparison
For the Medical Distribution subindustry, E For L Aim PCL's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL Days Sales Outstanding vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's Days Sales Outstanding falls into.
E For L Aim PCL Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
E For L Aim PCL (BKK:EFORL-R) has a Days Sales Outstanding of 92.45 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on E For L Aim PCL and its competitors. This is near median its historical median of 101.87. Over the past decade, E For L Aim PCL's Days Sales Outstanding has ranged from 74.48 to 109.26. According to the industry distribution chart, E For L Aim PCL ranks #76 out of 118 companies in the Medical Distribution industry, placing it in the top 64.4%.
Is E For L Aim PCL's Days Sales Outstanding too high?
E For L Aim PCL's current Days Sales Outstanding of 92.45 is near median its 10-year median of 101.87. Over the past 10 years, this metric has ranged from a low of 74.48 to a high of 109.26. The Medical Distribution industry median Days Sales Outstanding is 74.92. E For L Aim PCL's value of 92.45 is 23.4% above this industry median. Based on the distribution chart, E For L Aim PCL ranks #76 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, E For L Aim PCL has a GF Score™ of 40/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's Days Sales Outstanding compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #76 out of 118 companies for Days Sales Outstanding. This places E For L Aim PCL in the lower half of its industry. The industry median Days Sales Outstanding is 74.92. E For L Aim PCL's value of 92.45 is 23.4% above this benchmark. Historically, E For L Aim PCL's own Days Sales Outstanding has ranged from 74.48 to 109.26 over the past decade. While the company's 10-year median is 101.87 vs. the industry median of 74.92, E For L Aim PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Distribution company?
The median Days Sales Outstanding among Medical Distribution companies is 74.92, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. E For L Aim PCL's current Days Sales Outstanding of 92.45 is 23.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on E For L Aim PCL and its competitors. For the Medical Distribution industry, the median Days Sales Outstanding is 74.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current Days Sales Outstanding is 92.45, which is near median its own 10-year median of 101.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.14, compared to a current price of ฿0.12 — trading 14.3% below its estimated fair value. The current Days Sales Outstanding is 92.45, which is near median its 10-year median of 101.87 and 23.4% above the Medical Distribution industry median of 74.92. E For L Aim PCL's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL-R), the current Days Sales Outstanding is 92.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL-R) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 14.3% below its estimated GF Value™ of ฿0.14.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL-R:
Days Sales Outstanding: 92.45 (near median its 10-year median of 101.87)
GF Value™: ฿0.14 vs. price of ฿0.12 (14.3% below fair value)
Industry Position: 23.4% above the Medical Distribution median (#76 of 118)
No single metric tells the full story. See the BKK:EFORL-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
40GF Score
Get the complete analysis for BKK:EFORL-R
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL-R has been successfully added to your 
